We have a buy signal on IDH. One aspect of our buy signal is saying caution, however, worth taking some more of this share.

IDH have announced that they can enter the US market with their Direct Renin assay.

Used to find the amount of active renin present in the blood. Results of the test are used to assist clinicians in the investigation of hypertension-related disorders such as primary aldosteronism and renovascular hypertension. A fast and reliable alternative to existing manual methods, and a necessity when screening in extended hypertensive populations.

Hypertension is the third leading cause of death after malnutrition and diseases related to smoking. One in every three American adults has high blood pressure.

IDS first launched the automated Direct Renin immunoassay in Europe in June 2012.